Second Opinion October 4, 2024
Christina Farr

Important new data is out today indicating that might be the case — and for the very reason you might expect!

I am stunned. The Financial Times reported today that there’s been a dip in obesity rates this year, indicating that we may have already hit the peak and could see a slow and steady decline from here.

What’s driving that? Data columnist John Burn-Murdoch suggests that it might very well be the GLP-1 medicines, given that 1 in 8 members of the public have now tried these drugs per data from KFF. Moreover, he noted, that the drop...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article